Chronic Venous Insufficiency in Adults Over 50
Overview and Pathophysiology
Chronic venous insufficiency (CVI) develops when incompetent venous valves allow retrograde blood flow, creating venous hypertension that progressively damages the vein wall and surrounding tissues. 1
The underlying mechanism involves:
- Loss of elasticity in the vein wall causing valve leaflets to fail to close properly, allowing blood to flow backward from proximal to distal and from deep to superficial veins 1
- Increased venous pressure from reflux causes veins to become elongated and tortuous 1
- Shear stress on endothelial cells from reversed or turbulent blood flow triggers inflammation and progressive tissue damage 1
Risk Factors
Established risk factors include family history of venous disease, female sex, older age, chronically increased intra-abdominal pressure (obesity, pregnancy, chronic constipation, tumors), prolonged standing, prior deep venous thrombosis, and arteriovenous shunting. 1, 2
Key modifiable factors:
- Obesity and prolonged standing significantly increase venous pressure 1, 2
- Prior deep vein thrombosis damages valves and causes secondary revascularization 1, 2
- Pregnancy and multiparity in women increase risk through hormonal and mechanical factors 2
Clinical Presentation
Symptom Patterns
Localized symptoms include pain, burning, itching, and tingling at varicose vein sites, while generalized symptoms consist of aching, heaviness, cramping, throbbing, restlessness, and leg swelling. 1
Critical diagnostic features:
- Symptoms worsen at day's end after prolonged standing and improve with leg elevation 1
- Women report lower limb symptoms significantly more often than men 1
- Symptom severity increases with advancing CEAP clinical class 1
CEAP Classification System
The clinical classification ranges from C0 (no visible venous disease) to C6 (active venous ulcer): 1
- C0-C1: No visible veins or telangiectasias only
- C2: Varicose veins (≥3mm diameter)
- C3: Edema without skin changes
- C4: Skin changes (pigmentation, eczema, lipodermatosclerosis)
- C5: Healed venous ulcer
- C6: Active venous ulcer
Signs of Advanced Disease
Warning signs of serious underlying vascular insufficiency include skin pigmentation changes, eczema, infection, superficial thrombophlebitis, venous ulceration, subcutaneous tissue loss, and lipodermatosclerosis. 1
Diagnostic Work-Up
Initial Assessment
Obtain a comprehensive history focusing on family history of deep vein thrombosis and varicose veins, prior DVT episodes, pregnancy history, occupational standing requirements, and symptom patterns. 3
Duplex Ultrasound (Mandatory Before Intervention)
Venous duplex ultrasonography is the diagnostic modality of choice when venous disease is severe or interventional therapy is being considered. 4
Required documentation includes: 4
- Vein diameter at specific anatomic landmarks (minimum 2.5mm for sclerotherapy, ≥4.5mm for thermal ablation)
- Reflux duration at saphenofemoral or saphenopopliteal junction (pathologic if ≥500 milliseconds)
- Assessment of deep venous system patency to exclude DVT
- Location and extent of all refluxing segments including perforator veins
- Identification of incompetent junctions and their specific measurements
Advanced Imaging
CT venography or MR venography may be indicated in selected patients with suspected deep venous obstruction or complex anatomy who might benefit from invasive intervention. 3
Management Algorithm
Step 1: Conservative Management (First-Line for All Patients)
Prescribe medical-grade gradient compression stockings delivering 20-30 mmHg minimum pressure for a documented 3-month trial before considering interventional treatment. 4
Additional conservative measures: 1, 4
- Leg elevation when resting to reduce venous pressure
- Regular calf-pump-enhancing exercise to improve venous return
- Weight loss if overweight or obese
- Avoidance of prolonged standing or sitting to minimize venous pooling
Important caveat: Compression stockings alone have no proven benefit in preventing post-thrombotic syndrome or treating established venous insufficiency when significant reflux (≥500ms) is present. 4 Recent randomized trials show compression therapy does not prevent disease progression in patients with documented reflux. 4
Step 2: Pharmacologic Adjuncts
Horse chestnut seed extract (Aesculus hippocastanum) and other phlebotonics may ease symptoms of varicose veins, though long-term safety and effectiveness studies are lacking. 1
Micronized purified flavonoid fraction (MPFF) shows promise in relieving symptoms and preventing morbidity, representing renewed interest in nutritional supplements. 3
Avoid relying on diuretics or topical steroid creams as they reduce swelling and pain only short-term with no long-term treatment advantage. 5
Step 3: Interventional Treatment Indications
Referral for interventional treatment should not be delayed for a trial of external compression when valvular reflux is documented; interventional treatment should be offered if valvular reflux is documented. 1
Specific criteria for intervention: 4
- Documented reflux ≥500 milliseconds at saphenofemoral or saphenopopliteal junction
- Severe and persistent symptoms (pain, swelling, heaviness) interfering with activities of daily living
- Failed 3-month trial of medical-grade compression stockings (20-30 mmHg)
- Skin changes (CEAP C4) or venous ulceration (C5-C6) indicating disease progression
Step 4: Interventional Treatment Selection
For Main Saphenous Trunks (GSV/SSV) with Junctional Reflux
Endovenous thermal ablation (radiofrequency or laser) is first-line treatment for saphenofemoral or saphenopopliteal junction reflux when vein diameter ≥4.5mm with reflux ≥500ms, achieving technical success rates of 91-100% at 1 year. 4
Endovenous laser ablation may be better tolerated than sclerotherapy and surgery, with fewer adverse effects and equal effectiveness. 1
Advantages over surgery: 4
- Similar efficacy with 91-100% occlusion rates at 1 year
- Improved early quality of life and reduced hospital recovery
- Fewer complications including reduced bleeding, hematoma, wound infection, and paresthesia
Risks to counsel patients about: 4
- Approximately 7% risk of temporary nerve damage from thermal injury
- Deep vein thrombosis in 0.3% of cases
- Pulmonary embolism in 0.1% of cases
- Early postoperative duplex scan (2-7 days) mandatory to detect endovenous heat-induced thrombosis
For Tributary Veins and Smaller Vessels
Foam sclerotherapy (including Varithena/polidocanol) is appropriate for tributary veins with diameter 2.5-4.5mm, achieving occlusion rates of 72-89% at 1 year. 4
Critical treatment sequencing: Treating junctional reflux with thermal ablation is mandatory before or concurrent with tributary sclerotherapy to prevent recurrence rates of 20-28% at 5 years. 4 Chemical sclerotherapy alone has inferior long-term outcomes at 1-, 5-, and 8-year follow-ups compared to thermal ablation. 4
**Vessels <2.0mm diameter** treated with sclerotherapy have only 16% primary patency at 3 months compared with 76% for veins >2.0mm, making treatment of very small vessels futile. 4
Common side effects of foam sclerotherapy: 4
- Phlebitis, new telangiectasias, and residual pigmentation are common
- Transient colic-like pain resolving within 5 minutes
- Deep vein thrombosis is exceedingly rare
For Large Bulging Tributary Veins
Ambulatory phlebectomy (stab phlebectomy) is medically necessary as adjunctive treatment for symptomatic varicose tributary veins >4mm when performed concurrently with treatment of saphenofemoral junction reflux. 4
Critical anatomic consideration: The common peroneal nerve near the fibular head must be avoided during lateral calf phlebectomy to prevent foot drop. 4
Step 5: Special Considerations for Advanced Disease
For patients with venous ulceration (C5-C6), referral for endovenous thermal ablation should not be delayed for compression therapy trials, as the presence of ulceration represents severe disease warranting immediate intervention. 4
For patients with skin changes (C4 disease including pigmentation, eczema, lipodermatosclerosis), intervention is required to prevent progression even when severe pain is not the primary complaint. 4
Common Pitfalls and How to Avoid Them
Pitfall 1: Treating Tributaries Without Addressing Junctional Reflux
Untreated saphenofemoral or saphenopopliteal junction reflux causes persistent downstream pressure, leading to tributary vein recurrence even after successful sclerotherapy. 4 Always treat junctional reflux first or concurrently with tributary treatment.
Pitfall 2: Inadequate Ultrasound Documentation
Exact vein diameter measurements at specific anatomic landmarks are mandatory to avoid inappropriate treatment selection. 4 Vague descriptions like "moderate reflux" or "enlarged vein" are insufficient for medical necessity determination.
Pitfall 3: Insufficient Conservative Management Trial
Insurance policies require documented 3-month trial of prescription-grade compression stockings (20-30 mmHg minimum) with symptom diary before approval for interventional treatment. 4 However, this requirement should not delay treatment in patients with ulceration or advanced skin changes (C4-C6).
Pitfall 4: Treating Veins Below Size Thresholds
Treating veins <2.5mm diameter results in poor outcomes with only 16% patency at 3 months. 4 Strict adherence to size criteria (≥2.5mm for sclerotherapy, ≥4.5mm for thermal ablation) ensures appropriate patient selection and reduces recurrence.
Pitfall 5: Overlooking Deep Venous System Assessment
Always assess deep venous system patency before intervention to exclude DVT and identify patients with post-thrombotic syndrome who may have different treatment needs. 4
Expected Outcomes and Follow-Up
Endovenous thermal ablation demonstrates 91-100% technical success with 96% patient satisfaction at 1 year. 4
Foam sclerotherapy produces 72-89% occlusion rates at 1 year but has higher long-term recurrence compared to thermal ablation. 4
Traditional surgical treatment has 20-28% recurrence rates at 5 years, highlighting the importance of proper treatment sequencing and addressing junctional reflux. 4
Long-term follow-up ultrasound at 3-6 months is needed to assess treatment success and identify residual incompetent segments requiring adjunctive therapy. 4